Status:

COMPLETED

Pilot Study of Duloxetine in Adult Attention Deficit Hyperactivity Disorder(ADHD)

Lead Sponsor:

Université de Montréal

Collaborating Sponsors:

Centre hospitalier de l'Université de Montréal (CHUM)

Conditions:

Attention Deficit Disorder With Hyperactivity

Eligibility:

All Genders

18-50 years

Phase:

PHASE2

Brief Summary

The purpose of this study is to determine whether duloxetine is an effective treatment of attention deficit disorder in adults.

Eligibility Criteria

Inclusion

  • Clinical diagnosis of ADHD of at least moderate intensity
  • Able to give consent
  • Able to swallow capsules

Exclusion

  • Allergic or do not tolerate duloxetine
  • Under psychotherapy for ADHD
  • Taking a medication that interacts with duloxetine, including all psychotropic medication
  • Treated with medication for ADHD
  • Unstable medical condition
  • Severe renal insufficiency
  • Liver insufficiency
  • Substance/alcool abuse or dependency in the last 6 months
  • Pregnancy, nursing or inadequate contraceptive methods
  • Suicide or homicide risk
  • Organic brain syndrome
  • Any diagnosis of lifetime bipolar disorder or psychotic disorder, and any actual diagnosis of anxious disorder or major depressive disorder

Key Trial Info

Start Date :

August 1 2009

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

December 1 2010

Estimated Enrollment :

40 Patients enrolled

Trial Details

Trial ID

NCT00940693

Start Date

August 1 2009

End Date

December 1 2010

Last Update

December 14 2010

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Centre Hospitalier Universitaire de Montréal: Hôpital Notre-Dame

Montreal, Quebec, Canada, H2L 4M1